{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:23:42Z","timestamp":1787239422594,"version":"build-2736575974"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.euroneuro.2023.11.008","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:30:45Z","timestamp":1703118645000},"page":"25-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Teratogenicity of valproate: Further reasons for action"],"prefix":"10.1016","volume":"80","author":[{"given":"Gerard","family":"Anmella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.euroneuro.2023.11.008_bib0001","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40264-023-01314-3","article-title":"Impact of 2018 EU risk minimisation measures and revised pregnancy prevention programme on utilisation and prescribing trends of medicinal products containing valproate: an interrupted time series study","volume":"46","author":"Abtahi","year":"2023","journal-title":"Drug Saf."},{"issue":"11","key":"10.1016\/j.euroneuro.2023.11.008_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.euroneuro.2019.09.007","article-title":"Expert advice on the management of valproate in women with bipolar disorder at childbearing age","volume":"29","author":"Anmella","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.11.008_bib0003","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.euroneuro.2023.06.002","article-title":"Prevention and treatment of Postpartum Mania, Psychosis, and psychotic depression","volume":"74","author":"Bergink","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.euroneuro.2023.11.008_bib0004","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/pds.4881","article-title":"Did advice on the prescription of sodium valproate reduce prescriptions to women? An observational study in three European countries between 2007 and 2016","volume":"28","author":"Charlton","year":"2019","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.euroneuro.2023.11.008_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.euroneuro.2023.08.501","article-title":"Is it stress or is it the hormones? Perinatal depression in fathers","volume":"77","author":"Chechko","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.euroneuro.2023.11.008_bib0006","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1111\/epi.17085","article-title":"Prenatal exposure to valproate and risk of congenital malformations\u2014Could we have known earlier?\u2014A population-based cohort study","volume":"62","author":"Christensen","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.euroneuro.2023.11.008_bib0007","unstructured":"EUPAS34201. (2023). European network of centres for pharmacoepidemiology and pharmacovigilance (ENCEPP). Study protocol EUPAS34201. https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=105970. (accessed 29\/11\/23)."},{"key":"10.1016\/j.euroneuro.2023.11.008_bib0008","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.euroneuro.2021.08.264","article-title":"Preventing new episodes of bipolar disorder in adults: systematic review and meta-analysis of randomized controlled trials","volume":"54","author":"Nestsiarovich","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.euroneuro.2023.11.008_bib0009","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/pds.5318","article-title":"Bipolar disorder prevalence and psychotropic medication utilisation in Hong Kong and the United Kingdom","volume":"30","author":"Ng","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"10.1016\/j.euroneuro.2023.11.008_bib0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2023.11.008_bib0011","article-title":"Lamotrigine efficacy, safety, and tolerability for women of childbearing age with bipolar I disorder: meta-analysis from four randomized, placebo-controlled maintenance studies","author":"Vieta","year":"2023","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23007228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23007228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:07:26Z","timestamp":1760378846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X23007228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":11,"alternative-id":["S0924977X23007228"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.11.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teratogenicity of valproate: Further reasons for action","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}